Agonist of the adenosine A(3) receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of gamma-irradiated mice

0427968 - BFÚ 2015 RIV DE eng J - Journal Article
Hofer, Michal - Pospíšil, Milan - Dušek, L. - Hoferová, Zuzana - Komůrková, Denisa
Agonist of the adenosine A(3) receptor, IB-MECA, and inhibitor of cyclooxygenase-2, meloxicam, given alone or in a combination early after total body irradiation enhance survival of gamma-irradiated mice.
Radiation and Environmental Biophysics. Roč. 53, č. 1 (2014), s. 211-215. ISSN 0301-634X. E-ISSN 1432-2099
R&D Projects: GA ČR(CZ) GA305/08/0158; GA ČR(CZ) GAP303/11/0128
Institutional support: RVO:68081707
Keywords : Ionizing radiation * Acute radiation disease * Survival
Subject RIV: BO - Biophysics
Impact factor: 1.528, year: 2014

here exists a requirement for drugs which would be useful in therapy of an acute radiation damage of a mammalian organism. The aim of the study was to evaluate survival parameters in mice exposed to a lethal gamma-ray dose of 8.5 Gy and treated with single doses of an adenosine A(3) receptor agonist, IB-MECA, or a cyclooxygenase-2 (COX-2) inhibitor, meloxicam, administered alone or in a combination early after irradiation, i.e., 0.5 and 1 h post-irradiation, respectively. The assessed parameters were the mean survival time (MST) and the cumulative percentage 30-day survival (CPS). Administrations of single intraperitoneal doses of either IB-MECA 0.5 h post-irradiation or meloxicam 1 h post-irradiation resulted in statistically significant increases of MST in comparison with the control irradiated mice. Combined administration of IB-MECA and meloxicam was found to be the only treatment statistically enhancing the parameter of CPS and to lead to the most expressive increase in MST of the experimental mice.
Permanent Link: http://hdl.handle.net/11104/0233408